Cargando…

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection

BACKGROUND: Recurrent Clostrioides difficile infection (rCDI) is a public health threat associated with intestinal microbiome disruption (dysbiosis), which is postulated to increase CDI recurrence risk via disruption of bile acid(BA)-mediated resistance to C. difficile colonization. RBX2660 is an in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferdyan, Nicky, Papazyan, Romeo, Walsh, Dana, Klein, Sarah, Qi, Steve, Blount, Ken, Srinivasan, Karthik, Fuchs, Bryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Oral Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776024/ http://dx.doi.org/10.1093/ofid/ofaa417.028

Ejemplares similares

1039. Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
por: Papazyan, Romeo, et al.
Publicado: (2021)

30. Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-based Therapeutic RBX7455 to Individuals with Recurrent clostrioides Difficile Infection
por: Walsh, Dana, et al.
Publicado: (2020)

Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
por: Papazyan, Romeo, et al.
Publicado: (2023)

129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
por: Hau, Heidi, et al.
Publicado: (2021)

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
por: Jones, Courtney, et al.
Publicado: (2019)

1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
por: Blount, Ken, et al.
Publicado: (2021)

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
por: Hau, Heidi, et al.
Publicado: (2019)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
por: Blount, Ken F, et al.
Publicado: (2019)

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
por: Khanna, Sahil, et al.
Publicado: (2017)

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
por: Orenstein, Robert, et al.
Publicado: (2022)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
por: Orenstein, Robert, et al.
Publicado: (2019)

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
por: Kwak, Suryang, et al.
Publicado: (2020)

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
por: Mische, Sarah, et al.
Publicado: (2018)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
por: Dubberke, Erik, et al.
Publicado: (2014)

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Braun, Tricia, et al.
Publicado: (2021)

Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report
por: Keen, Eric C, et al.
Publicado: (2020)

Health care consequences of hospitalization with Clostrioides difficile infection: a propensity score matching study
por: Hirsch, Bruce E., et al.
Publicado: (2022)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile
por: Buffie, Charlie G., et al.
Publicado: (2014)

2660. Infection Complications Following Mismatched Allogeneic Hematopoietic Cell Transplantation
por: Ebisu, Yosuke, et al.
Publicado: (2019)

2660. Evaluating Risk for Bacterial Vaginosis Utilizing an Unsupervised Machine Learning Approach
por: Rodriguez, Violeta, et al.
Publicado: (2023)

PB2660: HEREDITARY COAGULATION FACTOR FVII DEFICIENCY CAUSED BY COMPOUND HETEROZYGOUS MUTATIONS
por: Zhou, Rongfu, et al.
Publicado: (2023)

Aggregatibacter actinomycetemcomitans Outer Membrane Proteins 29 and 29 Paralogue Induce Evasion of Immune Response
por: da Silva, Maike Paulino, et al.
Publicado: (2022)

Clostridium difficile colitis – a serious current problem
por: Dumitru, Irina Magdalena, et al.
Publicado: (2013)

Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration
por: Blount, Ken, et al.
Publicado: (2022)

Epidemiological and clinical considerations on Clostridium difficile colitis in Braşov County
por: Cocuz, Maria Elena, et al.
Publicado: (2014)

Clostridium difficile infection in medical wards – a mathematical model
por: Schechner, V, et al.
Publicado: (2015)

29. Sustained Recovery in Patients Admitted to Hospital With COVID-19
por: Moestrup, Kasper S, et al.
Publicado: (2021)

Clinical utility of the GeneXpert assay for the diagnosis of Clostridium difficile infections
por: Florea, Dragoş, et al.
Publicado: (2014)

Recurrence and mortality following treatment for Clostridum difficile infection with metronidazole or vancomycin
por: Stevens, V, et al.
Publicado: (2015)

Prevalence of asymptomatic Clostridium difficile colonization in tertiary hospital patients in Australia
por: Kanamori, L Furuya, et al.
Publicado: (2015)

A Small RNA Encoded in the Rv2660c Locus of Mycobacterium tuberculosis Is Induced during Starvation and Infection
por: Houghton, Joanna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_366v305imn840p52k8siv3h4kj